Across TCGA pan-cancer cohorts, IGLV9-49 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of IGLV9-49’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where IGLV9-49 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types IGLV9-49 is over-expressed in tumor, although a few such as HNSC and COAD show the opposite, repressed pattern.

HNSC, COAD, and PDAC are the cancer types where IGLV9-49 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLV9-49 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	−1.151	<.001	8	view →
COAD	All	III,IV	−0.469	.004	6	view →
PDAC	Female	All	+0.738	<.001	4	view →
LUAD	All	All	−0.370	.002	2	view →
LSCC	Male	All	−0.352	.031	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: IGLV9-49 RNA expression & survival · all IGLV9-49 data types